UNLABELLED: To assess the prescription patterns of anti-osteoporosis medications, three cross-sectional analyses were performed between 2004 and 2006. Women aged 50 and older were identified from the health insurance claims database of the Rhône-Alpes area. HRT prescriptions decreased while bisphosphonates and raloxifene prescriptions increased, respectively, in different age groups. INTRODUCTION: The objective of this study was to assess the prescription patterns of hormone replacement therapy (HRT) and anti-osteoporosis medications (AOM) in post-menopausal French women since the WHI and the revision of the French clinical practice guidelines in 2004. METHODS: Three cross-sectional analyses were performed between 2004 and 2006. Women aged 50 and older who had at least one claim for a prescription for HRT, bisphosphonates or raloxifene were identified from health insurance claims database of the Rhône-Alpes area. RESULTS: A 39% decrease in the number of women who had HRT was observed (67,241 to 41,024). Twenty-one percent and 18% increases were observed, respectively, for bisphosphonates (39,192 to 47,395) and raloxifene (10,263 to 12,060). HRT and raloxifene were mainly prescribed to women aged 55 to 64 (58% and 39%, respectively), bisphosphonates to women aged 65 to 84 (70%). Ninety-eight percent of women had HRT prescribed by a gynaecologist or a general practitioner (GP). Most AOM were prescribed by a GP; 13% of women had AOM prescribed by a rheumatologist. CONCLUSION: Prescriptions for HRT in post-menopausal French women have significantly decreased while bisphosphonates and raloxifene prescriptions have increased, respectively, in different age groups but to a lesser extent than the HRT decrease.
UNLABELLED: To assess the prescription patterns of anti-osteoporosis medications, three cross-sectional analyses were performed between 2004 and 2006. Women aged 50 and older were identified from the health insurance claims database of the Rhône-Alpes area. HRT prescriptions decreased while bisphosphonates and raloxifene prescriptions increased, respectively, in different age groups. INTRODUCTION: The objective of this study was to assess the prescription patterns of hormone replacement therapy (HRT) and anti-osteoporosis medications (AOM) in post-menopausal French women since the WHI and the revision of the French clinical practice guidelines in 2004. METHODS: Three cross-sectional analyses were performed between 2004 and 2006. Women aged 50 and older who had at least one claim for a prescription for HRT, bisphosphonates or raloxifene were identified from health insurance claims database of the Rhône-Alpes area. RESULTS: A 39% decrease in the number of women who had HRT was observed (67,241 to 41,024). Twenty-one percent and 18% increases were observed, respectively, for bisphosphonates (39,192 to 47,395) and raloxifene (10,263 to 12,060). HRT and raloxifene were mainly prescribed to women aged 55 to 64 (58% and 39%, respectively), bisphosphonates to women aged 65 to 84 (70%). Ninety-eight percent of women had HRT prescribed by a gynaecologist or a general practitioner (GP). Most AOM were prescribed by a GP; 13% of women had AOM prescribed by a rheumatologist. CONCLUSION: Prescriptions for HRT in post-menopausal French women have significantly decreased while bisphosphonates and raloxifene prescriptions have increased, respectively, in different age groups but to a lesser extent than the HRT decrease.
Authors: L Pérez-Edo; M Ciria Recasens; C Castelo-Branco; P Orozco López; A Gimeno Marqués; C Pérez; J Manasanch Dalmau Journal: Osteoporos Int Date: 2004-01-27 Impact factor: 4.507
Authors: Camil Castelo-Branco; Santiago Palacios; Joaquín Calaf; Francisco Vázquez; Juan Luis Lanchares Journal: Maturitas Date: 2005-10-04 Impact factor: 4.342
Authors: Anthony B Hodsman; Douglas C Bauer; David W Dempster; Larry Dian; David A Hanley; Steven T Harris; David L Kendler; Michael R McClung; Paul D Miller; Wojciech P Olszynski; Eric Orwoll; Chui Kin Yuen Journal: Endocr Rev Date: 2005-03-15 Impact factor: 19.871
Authors: Joann E Manson; Shari S Bassuk; S Mitchell Harman; Eliot A Brinton; Marcelle I Cedars; Rogerio Lobo; George R Merriam; Virginia M Miller; Frederick Naftolin; Nanette Santoro Journal: Menopause Date: 2006 Jan-Feb Impact factor: 2.953
Authors: Elizabeth Barrett-Connor; Deborah Grady; Andreas Sashegyi; Pamela W Anderson; David A Cox; Krzysztof Hoszowski; Pentti Rautaharju; Kristine D Harper Journal: JAMA Date: 2002-02-20 Impact factor: 56.272
Authors: B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings Journal: JAMA Date: 1999-08-18 Impact factor: 56.272
Authors: Rowan T Chlebowski; Wendy Barrington; Aaron K Aragaki; JoAnn E Manson; Gloria Sarto; Mary J OʼSullivan; Daniel Wu; Jane A Cauley; Lihong Qi; Robert L Wallace; Ross L Prentice Journal: Menopause Date: 2017-02 Impact factor: 2.953
Authors: Rowan T Chlebowski; Zhao Chen; Jane A Cauley; Garnet Anderson; Rebecca J Rodabough; Anne McTiernan; Dorothy S Lane; Joann E Manson; Linda Snetselaar; Shagufta Yasmeen; Mary Jo O'Sullivan; Monika Safford; Susan L Hendrix; Robert B Wallace Journal: J Clin Oncol Date: 2010-06-21 Impact factor: 44.544
Authors: Jeffrey R Curtis; Qian Cai; Sally W Wade; Bradley S Stolshek; John L Adams; Akhila Balasubramanian; Hema N Viswanathan; Joel D Kallich Journal: Bone Date: 2013-03-15 Impact factor: 4.398
Authors: A Reymondier; P Caillet; F Abbas-Chorfa; V Ambrosi; S B Jaglal; R Chapurlat; A-M Schott Journal: Osteoporos Int Date: 2012-05-16 Impact factor: 4.507
Authors: M T Bazelier; T-P van Staa; B M J Uitdehaag; C Cooper; H G M Leufkens; P Vestergaard; R M C Herings; F de Vries Journal: Neurology Date: 2012-05-16 Impact factor: 9.910